II. Indications: Type II Diabetes Mellitus (early, phase 1-2)
- Better effect in lean patients
- Consider when Hemoglobin A1C <9%
- Second-line to Metformin in most patients
- Consider as first-line in specific cohorts
III. Contraindications
- Sulfa Allergy (applies to sulonylureas)
- Renal and liver dysfunction
- Use caution with Sulfonylureas (especially Glyburide)
- Repaglinide or Nateglinide may be preferred here
- Avoid most Sulfonylureas when GFR <60 ml/min (higher risk of Hypoglycemia)
- Glipizide Half-Life is not impacted by lower GFR and is safer to use in low GFR
- Avoid Glyburide in cardiovascular disease (and in general due to Hypoglycemia risk)
- Glimepiride and Glipizide do not appear to increase risk
IV. Mechanism
-
Sulfonylureas stimulate Potassium channel closure on pancreatic beta cell surface
- Triggers Insulin release
- Secretagogues do not burn out the beta cells sooner
V. Dosing: Pearls
- Use Long acting agents
- Increase dose every 1-2 weeks until adequate response
- No response in 25-30% of Type II Diabetics
- Never combine secretagogues
- They all have same site of activity
- If one does not work, then all will not work
VI. Medications: Glimepiride
- Glimepiride (Amaryl)
- Start: 1-2 mg orally daily taken orally with breakfast
- Usual: 4 mg orally daily
- Maximum: 8 mg orally daily (doses above 4 mg daily, are unlikely to offer benefit)
- Advantages
- More rapid onset with longer duration
- Lower Incidence of Hypoglycemia than Glyburide, but greater risk than Glipizide
- Risk of Hypoglycemia increases with lower GFR
- Preferred of class for Coronary Artery Disease
VII. Medications: Glipizide
- Glipizide (Glucotrol)
- Start: 5 mg orally daily
- Usual: 10-20 mg orally daily
- Maximum: 20 mg orally twice daily
- Glipizide Extended Release (Glucotrol XL)
- Start: 5 mg orally daily taken 30 minutes before breakfast
- Usual: 5-10 mg orally daily
- Maximum: 20 mg orally daily
- Doses above 10 mg daily ER, are unlikely to offer benefit (divide twice daily if used)
- Advantages: Least expensive Sulfonylurea
- Disadvantages: Extended release may increase Hypoglycemia risk when compared with immediate release
VIII. Medications: Glyburide
- Precautions
- Glipizide may be preferred instead due to increased risks of Hypoglycemia associated with Glyburide, Glimepiride
- Other agents are generic (no cost advantage to Glyburide)
- Glyburide has been associated with worse cardiovascular outcomes in patients presenting for emergent PCI
- Glyburide appears to predispose to more severe Hypoglycemia than the other Second Generation Sulfonylureas
- Avoid in older adults
- Glyburide should be avoided in renal dysfunction where GFR <50-60 mL/min (increases hypglycemia risk)
- Glyburide should be avoided in severe hepatic dysfunction (increases Hypoglycemia risk)
- Gangji (2007) Diabetes Care 30:389-94 [PubMed]
- Glipizide may be preferred instead due to increased risks of Hypoglycemia associated with Glyburide, Glimepiride
- Glyburide (DiaBeta, Micronase)
- Start: 2.5 to 5 mg orally daily with breakfast
- Usual: 5-20 mg orally daily
- Maximum: 20 mg orally daily
- Glyburide Micronized (Glynase, PresTab)
- Start: 1.5 to 3 mg orally daily with breakfast
- Usual: 3-12 mg orally daily
- Maximum: 12 mg orally daily
IX. Adverse Effects
- Weight gain
-
Hypoglycemia
- Higher risk of severe Hypoglycemia with Glyburide than other Sulfonylureas
- Hypoglycemia risk increases with lower GFR
- See Drug Interactions below for concurrent agents that increase Hypoglycemia risk
- Cardiovascular Disease does not appear to be at increased risk with Sulfonylureas
- Early studies had suggested possible increased Cardiovascular Risk
- Sulfonylureas appear to be neutral in their Cardiovascular Risk effects
- Contrast with GLP-1 Agonists and SGLT2 Inhibitors which reduce Cardiovascular Risk
- (2019) presc lett 26(12): 71
X. Drug Interactions: Increased risk of Hypoglycemia with Sulfonylureas
XI. Efficacy
- Lower Hemoglobin A1C 0.8 to 1.5%
- Do not affect all-cause mortality
Images: Related links to external sites (from Bing)
Related Studies
glipizide (on 10/19/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GLIPIZIDE 10 MG TABLET | Generic | $0.05 each |
GLIPIZIDE 5 MG TABLET | Generic | $0.03 each |
GLIPIZIDE ER 10 MG TABLET | Generic | $0.17 each |
GLIPIZIDE ER 2.5 MG TABLET | Generic | $0.14 each |
GLIPIZIDE ER 5 MG TABLET | Generic | $0.11 each |
GLIPIZIDE XL 10 MG TABLET | Generic | $0.17 each |
GLIPIZIDE XL 2.5 MG TABLET | Generic | $0.14 each |
GLIPIZIDE XL 5 MG TABLET | Generic | $0.11 each |
GLIPIZIDE-METFORMIN 2.5-250 MG | Generic | $0.29 each |
GLIPIZIDE-METFORMIN 2.5-500 MG | Generic | $0.26 each |
GLIPIZIDE-METFORMIN 5-500 MG | Generic | $0.27 each |
glyburide (on 6/21/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GLYBURIDE 1.25 MG TABLET | Generic | $0.07 each |
GLYBURIDE 2.5 MG TABLET | Generic | $0.09 each |
GLYBURIDE 5 MG TABLET | Generic | $0.06 each |
GLYBURIDE MICRO 3 MG TABLET | Generic | $0.15 each |
GLYBURIDE MICRO 6 MG TABLET | Generic | $0.20 each |
GLYBURIDE-METFORMIN 2.5-500 MG | Generic | $0.04 each |
GLYBURIDE-METFORMIN 5-500 MG | Generic | $0.05 each |
glimepiride (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GLIMEPIRIDE 1 MG TABLET | Generic | $0.04 each |
GLIMEPIRIDE 2 MG TABLET | Generic | $0.04 each |
GLIMEPIRIDE 4 MG TABLET | Generic | $0.04 each |